Research article

A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response


  • Immune checkpoint genes (ICGs) have recently been proven to perform instrumental functions in the maintenance of immune homeostasis and represent a promising therapeutic strategy; however, their expression patterns and prognostic values are not fully elucidated in hepatocellular carcinoma (HCC). In this investigation, we focused on establishing and validating a prognostic gene signature to facilitate decision-making in clinical practice. Clinical information, as well as transcriptome data, was obtained from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) database. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) Cox method were employed to build a multi-gene signature in the TCGA database, while the ICGC database was used for validation. Subsequently, utilizing the six-gene signature, we were able to categorize patients into high- and low-risk groups. In two cohorts, survival analysis findings revealed a dismal outlook for the high-risk group. The receiver operating characteristic curves were utilized to estimate the gene signature's prediction ability. Moreover, correlation analysis showed high-risk group was linked to advanced pathological stage, infiltration of immune cells and therapeutic response. In summary, this unique gene profile might serve not only as a useful prognostic indicator but also as a marker of therapy responsiveness in HCC.

    Citation: Siyuan Tian, Yinan Hu, Chunmei Yang, Jiahao Yu, Jingyi Liu, Guoyun Xuan, Yansheng Liu, Keshuai Sun, Miao Zhang, Shuoyi Ma, Yulong Shang, Xia Zhou, Ying Han. A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response[J]. Mathematical Biosciences and Engineering, 2022, 19(5): 4719-4736. doi: 10.3934/mbe.2022220

    Related Papers:

    [1] Jiangshan Wang, Lingxiong Meng, Hongen Jia . Numerical analysis of modular grad-div stability methods for the time-dependent Navier-Stokes/Darcy model. Electronic Research Archive, 2020, 28(3): 1191-1205. doi: 10.3934/era.2020065
    [2] Linlin Tan, Bianru Cheng . Global well-posedness of 2D incompressible Navier–Stokes–Darcy flow in a type of generalized time-dependent porosity media. Electronic Research Archive, 2024, 32(10): 5649-5681. doi: 10.3934/era.2024262
    [3] Jiwei Jia, Young-Ju Lee, Yue Feng, Zichan Wang, Zhongshu Zhao . Hybridized weak Galerkin finite element methods for Brinkman equations. Electronic Research Archive, 2021, 29(3): 2489-2516. doi: 10.3934/era.2020126
    [4] Guoliang Ju, Can Chen, Rongliang Chen, Jingzhi Li, Kaitai Li, Shaohui Zhang . Numerical simulation for 3D flow in flow channel of aeroengine turbine fan based on dimension splitting method. Electronic Research Archive, 2020, 28(2): 837-851. doi: 10.3934/era.2020043
    [5] Jie Qi, Weike Wang . Global solutions to the Cauchy problem of BNSP equations in some classes of large data. Electronic Research Archive, 2024, 32(9): 5496-5541. doi: 10.3934/era.2024255
    [6] Jie Zhang, Gaoli Huang, Fan Wu . Energy equality in the isentropic compressible Navier-Stokes-Maxwell equations. Electronic Research Archive, 2023, 31(10): 6412-6424. doi: 10.3934/era.2023324
    [7] Zhonghua Qiao, Xuguang Yang . A multiple-relaxation-time lattice Boltzmann method with Beam-Warming scheme for a coupled chemotaxis-fluid model. Electronic Research Archive, 2020, 28(3): 1207-1225. doi: 10.3934/era.2020066
    [8] Guochun Wu, Han Wang, Yinghui Zhang . Optimal time-decay rates of the compressible Navier–Stokes–Poisson system in R3. Electronic Research Archive, 2021, 29(6): 3889-3908. doi: 10.3934/era.2021067
    [9] Wei Shi, Xinguang Yang, Xingjie Yan . Determination of the 3D Navier-Stokes equations with damping. Electronic Research Archive, 2022, 30(10): 3872-3886. doi: 10.3934/era.2022197
    [10] Xiaoxia Wang, Jinping Jiang . The uniform asymptotic behavior of solutions for 2D g-Navier-Stokes equations with nonlinear dampness and its dimensions. Electronic Research Archive, 2023, 31(7): 3963-3979. doi: 10.3934/era.2023201
  • Immune checkpoint genes (ICGs) have recently been proven to perform instrumental functions in the maintenance of immune homeostasis and represent a promising therapeutic strategy; however, their expression patterns and prognostic values are not fully elucidated in hepatocellular carcinoma (HCC). In this investigation, we focused on establishing and validating a prognostic gene signature to facilitate decision-making in clinical practice. Clinical information, as well as transcriptome data, was obtained from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) database. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) Cox method were employed to build a multi-gene signature in the TCGA database, while the ICGC database was used for validation. Subsequently, utilizing the six-gene signature, we were able to categorize patients into high- and low-risk groups. In two cohorts, survival analysis findings revealed a dismal outlook for the high-risk group. The receiver operating characteristic curves were utilized to estimate the gene signature's prediction ability. Moreover, correlation analysis showed high-risk group was linked to advanced pathological stage, infiltration of immune cells and therapeutic response. In summary, this unique gene profile might serve not only as a useful prognostic indicator but also as a marker of therapy responsiveness in HCC.



    Medical and health care has a bearing on the health of hundreds of millions of people and is a basic livelihood issue for people around the world. Specifically in China, the most populous country in the world, the total amount of medical resources is not abundant enough, resulting in an unbalanced supply and demand of medical services. According to information released by the National Health Commission of China, by the end of 2020, China had only 2.9 doctors per 1000 people, which means that there is only one doctor for every 300 people. To solve these problems, disease prediction has received increasing attention from academia and industry. While image-based [1] disease prediction has been well studied, research on text-based disease prediction [2] is still difficult due to the difficulty of understanding the Chinese language itself and obtaining a real and reliable clinical corpus.

    Since the National Health and Family Planning Commission of China issued the "Basic Specifications for Electronic Health Records (Trial), " many hospitals have accumulated a lot of electronic health records (EHRs). EHRs are detailed records of medical activities by medical personnel, mostly written by doctors, including structured data (lab tests, vital signs, etc.) and unstructured data (chief complaints, current illness history, etc.). With the development and popularity of EHRs, more and more scholars are interested in disease prediction. Existing work has focused on graph-based [3] methods and classification-based [4] methods for disease prediction from EHRs. Graph-based methods focus on the relationships between symptoms and diseases for disease prediction. Classification-based methods mainly extract features from EHRs and predict disease for patients. Early research is mainly based on manually designed rules and traditional machine learning methods. The rule-based method has a high accuracy rate, but the construction of the rules requires the participation of personnel in the medical field, which is time-consuming and labor-intensive. Traditional machine learning methods, such as Support Vector Machine (SVM) [5] and Random Forest [6], can avoid this problem, but it is difficult to express deeper semantic information of EHRs. With the development of deep learning, its application in disease prediction [7, 8] has significantly improved the performance. However, the existing methods mainly focus on a single type of structured medical data [9] but ignore the differences and connections between varied types of medical data [10]. Such as gender information in EHRs, may be insufficient for these texts to use the same encoder for representation. Furthermore, the information of entities in disease prediction is often ignored. In order to solve the above problems, we propose a novel disease prediction model with multi-type data, and the overall structure is shown in Figure 1.

    Figure 1.  Schematic diagram for predicting diseases.

    The contributions of this paper are as follows:

    1) Entity information is integrated with text information to better obtain the representation of EHRs.

    2) A multi-type data fusion model is proposed, which focuses on different ways to represent information respectively and improves obviously the accuracy of prediction and the interpretability of feature representations.

    3) Evaluation of real EHRs from a Three Grade Class B General Hospital in Gansu Province, China, shows that the multi-type data fusion model outperforms previous disease prediction methods with EHRs.

    Disease prediction is to use computer-related technology to extract features from EHRs and predict disease. Early research was mainly based on rules and knowledge reasoning expert systems [11]. Such methods are simple and easy to understand, but they require a lot of experts in the medical field to construct rules and are not flexible enough. With the continuous development of machine learning technology, more and more researchers apply these technologies for disease prediction. Palaniappand et al. [12] proposed a method for predicting heart disease using Naive Bayes and Decision Tree, which developed into a heart disease prediction system. Ananthakrishnan et al. [13] used logistic regression to diagnose Crohn's disease and ulcerative colitis. Drriseitl et al. [14] compared the algorithmic performances of K-nearest Neighbor, SVM and logistic regression in the diagnosis of skin diseases, and they found that SVM showed better performance.

    With the development of deep learning in NLP tasks, there are many ways to use deep learning methods for disease prediction. Yang et al. [15] proposed a Convolutional Neural Network (CNN) model to obtain textual information in EHRs and perform disease prediction. An et al. [16] obtained different features of EHRs based on the BiLSTM model and fused different types of features to predict cardiovascular disease. Wang et al. [17] proposed a prediction method based on BiLSTM and CNN to model characters and words in EHRs, respectively. Du et al. [18] utilized a multigraph structural LSTM model and considered the Spatio-temporal characteristics to predict foodborne diseases. Rasmy et al. [19] utilized the CovRNN model to learn the representations of patients with COVID-19 and make relevant predictions, such as mortality and hospital stay. Sha and Wang [20] proposed a hierarchical GRU-based model to predict clinical outcomes based on the medical code of the patient's previous visits. With the proposed pre-training models of ELMO [21], OpenAI GPT [22] and BERT [23], significant improvements have been achieved in various NLP tasks, which have also been applied in the medical field. Zhang et al. [24] proposed a BERT based model with an enhanced layer to encode EHRs for auxiliary diagnosis in obstetrics. BioBERT [25] is a pre-trained model that was trained on general and biomedical domain corpora. Mugisha et al. [26] utilized BioBERT to obtain representations in EHRs and make predictions of pneumonia diseases. These research methods have improved the accuracy of disease prediction to a certain extent, but there are still some shortcomings. On the one hand, the disease prediction models based on traditional machine learning are often limited by the shortcomings of feature engineering and the algorithm itself, and they are heavily dependent on manual rules, leading to the failure of generalization of the models. On the other hand, these methods are mainly modeled by a single type of data information, and few of them pay enough attention to different data types.

    In this paper, we propose a multi-type data fusion model based on EHRs, and the model structure is shown in Figure 2. The model can be divided into two parts: text representation and entity representation. The text representation module introduces BERT to get the encoded representation of the textual information; the encoding of the numerical information is achieved by one-hot and max-minimum normalization methods. Then, the textual and numerical encodings are sent to a multi-head self-attention layer, using the numerical information to enhance the text information and get a better text representation. The entity information is extracted by using the developed and relatively mature entity recognition technology. The pre-trained model BERT is used for encoding the characters of entities. Then, TextCNN is used for extracting features and obtaining entity representations. Finally, the two types of information are fused to get the final representation of the patient and make predictions about the disease.

    Figure 2.  The overall framework of the model for learning the representation of EHRs.

    The information contained in the EHRs text can be divided into structured and unstructured data. Unstructured data refers to textual information, while structured data refers to the information of demographics and physical examinations in this study, which are significant for disease prediction. For example, an older patient is more likely to have a cerebral infarction. It is considerable to convert structured data into numerical information for better representations. The specific situation is shown in Table 1.

    Table 1.  Numerical processing method for structured data.
    Initial description Gender:Female; Age:67; Marital Status:Married; Family History:None;
    T:36.8 ℃; P:62 beats/min; R:18 beats/min; Bp:140/90 mmHg
    Numerical information {(0, 67, 1, 0, 36.8, 62, 18, 140, 90)}

     | Show Table
    DownLoad: CSV

    Patient demographics include age, gender, marital status, family history and more. Only adult patients are concerned in this study, and their ages are split into 5 groups: (18, 25), (25, 45), (45, 65), (65, 89), (89, ). The patient's physical examination includes blood pressure (BP), heartbeat (R), pulse (P), body temperature (T), etc. The physical examination is encoded by max-min normalization. The demographic information is spliced to obtain the numerical representation of patients as Znum.

    Text information in the EHRs includes the chief complaint, history of present illness, etc. Using appropriate algorithms to extract features from EHRs texts can better help patients with disease prediction. Due to the sparseness of Chinese EHRs, traditional methods, such as Doc2vec, can not accurately obtain the text representation of Chinese EHRs. However, a pre-training model based on transfer learning can achieve better results after fine-tuning in small scale samples after pre-training in large data sets. Therefore, we utilize the pre-trained language model BERT to obtain textual representations of EHRs. The input text sequence is as follows:

    [CLS] Chinese Electronic Health Record [SEP]

    where, [CLS] indicates the start tag of the text, and [SEP] indicates the separator tag of the text. After the EHR is fed into the BERT model, the last layer of [CLS] is used to represent the entire EHR C. To better integrate numerical and textual information to obtain better text representations, we introduces the multi-head self-attention to enhance the textual representations of EHRs:

    Q=K=V=Wcconcat(Znum,C), (3.1)
    Attention(Q,K,V)=softmax(QKTdk)V, (3.2)
    Ztext=concat(head1,head2,,headh)Wowhere headi=Attention(QWQi,KWKi,VWVi), (3.3)

    where WiQ, WiK, WiV, Wc, Wo are trainable parameters, and Ztext is the final representation after enhancing of numerical information in the EHRs text.

    Through the analysis of EHRs, we found that entity type information (symptoms, medicine, etc.) is important for disease prediction. For example, the symptoms of "coughing" may increase the risk of bronchitis. Therefore, it is a great necessity of introducing relatively mature named entity recognition technology to extract entity information from EHRs. The BiLSTM-CRF model we use can easily extract entity information, which can obtain contextual information more comprehensively and learn the relationship between contexts easily, and convert the extracted context information into corresponding labels for each Chinese character. The architecture of the BiLSTM-CRF model is illustrated in Figure 3. In the model, the BIO (Begin, Inside, Outside) tagging scheme is used. First, the Skip-Gram [27] algorithm is introduced to train character embedding in EHRs. The sentence is represented as a sequence of characters vector Q=(q1,q2,...,qn), where n is the length of the EHRs. Secondly, the embeddings (q1,q2,...,qn) are given as input to the BiLSTM layer. In the BiLSTM layer and at step t, the output state of the forward LSTM is the hidden vector ht, and the output state of the other backward LSTM is hidden vectors ht. These two distinct networks use different parameters, and then the representation of a character ht=[ht;ht] is obtained by concatenating its forward and backward the hidden vector. Next, a full connection layer is used to map the hidden state vector (h1,h2,...,hn)Rn×m to k dimensions, where k is the number of labels in the label set. As a result, the sentence features are extracted that are represented as a matrix P=(p1,p2,...,pn)Rn×k. Finally, the parameters of the CRF layer are represented by a matrix A, and Aij denotes the score of the transition from the i-th label to the j-th label. Considering a sequence of labels y=(y1,y2,...,yn), the formula for calculating the score of the tag sequence is as follows.

    score(x,y)=ni=1Pi,yi+n+1j=1Ayj1,yj (3.4)
    Figure 3.  The architecture of BiLSTM-CRF model.

    The score of the whole sequence is equal to the sum of the scores of all words within the sentence, which is determined by the output matrix P of BiLSTM layer and the transition matrix A of the CRF layer. Then, a softmax function is used to yield the conditional probability of the path by normalizing the above score over all possible tag paths y.

    P(yx)=escore(x,y)ky=1escore(x,y) (3.5)

    During the training phase, the goal of this model is to maximize the log-probability of the correct tag sequence. In the prediction process, the score corresponding to each candidate sequence is calculated according to the trained parameters, and the optimal path is calculated using the Viterbi algorithm with dynamic programming as the core.

    argmaxyscore(x,y) (3.6)

    For input sequence S={x1,x2,...,xn} of the EHR, xi represents i-th character in the EHR. Inputting the sequence into the BERT model to obtain the representation of each character,

    H=[h1,h2,...,hn]=BERT([x1,x2,...,xn]). (3.7)

    Suppose that vectors hi to hj are the final hidden state vectors from BERT for symptom entity esyi; we apply the average operation to obtain a vector representation for each of the entities. This process can be mathematically formalized as:

    esyi=1ji+1jt=iht. (3.8)

    We get the symptom entity embeddings Esy=[esy1,esy2,...,esyn], and in the same way, we get the medicine and abnormal inspection result entity embeddings: Emed=[emed1,emed2,...,emedn], Eabn=[eabn1,eabn2,...,eabnn]. We separately performed convolution operations on the entity information of symptom, medicine and abnormal inspection results to extract various types of entity features. The convolution operation is carried out between convolution kernel w and symptom entity embedding in the ith window esyi:i+h1 in the symptom entity Esy and obtained feature csyi :

    csyi=f(esyi:i+h1w+b), (3.9)

    where the size of the convolution kernel is wRh×d, h is the height of the convolution kernel, and d is the dimension of the character embedding in BERT. bR is a bias term, and f is a non-linear function.

    This filter is applied to each possible window of features in the event matrix {esy1:h,esy2:h+1,...,esynh+1:n} to produce a feature map csy=[csy1,csy2,...,csynh+1]. Then, max pooling is applied over the feature map, and the average csy=max{csy} is taken. In the same way, we convolved medicine and abnormal inspection results information to obtain the medicine and abnormal inspection results representation cmed, cabn. The symptom, medicine and abnormal inspection results representation are spliced to obtain the final representation of the patient entity:

    Zentity=concat(csy;cmed;cabn). (3.10)

    By splicing the representation of text and entity information, the final representation of EHR is denoted as Zpatient=concat(Ztext;Zentity), where the size of this vector is the sum of the components dtext+dentity. The EHR representation Zpatient is sent to the fully connected layer, and the probability of each type of disease is calculated by the softmax activation function. The formula is

    y=softmax(wZpatient+b) (3.11)

    where y denotes the prediction probability distribution of K disease classes (K=9). yi indicates the probability that the input EHR is related to the i-th disease.

    In this paper, the cross-entropy loss function is used to train the model with the goal of minimizing the Loss:

    Loss=TCorpusKi=1yi(T)log(yi(T)) (3.12)

    where T is the input EHR, Corpus denotes training sample set and K is the number of classes.

    Large-scale Chinese EHRs datasets with entity information are not always readily accessible. To facilitate research on Chinese EHRs, we collected a large raw dataset in a Three Grade Class B Hospital General in Gansu Province, China, which contained 61, 233 EHRs. We select 8 kinds of diseases, including cerebral infarction (CI), vertebrobasilar insufficiency (VBI), coronary atherosclerotic heart disease (CAHD), cholecystitis, bronchitis, degenerative spondylitis, intestinal obstruction, type 2 diabetic peripheral neuropathy (T2DM), and select some other diseases as the Chinese Electronic Health Record dataset (CEHR). Before the experiments of our study, the following preprocessing was carried out on the CEHR text:

    1) De-privacy: Delete the patient's personal private information from CEHRs, such as: 'name', 'place of birth', 'occupation' and other private information.

    2) Selecting the required CEHRs: Chinese EHRs contain a large number of missing values. Therefore, those with unfilled personal information and less than 200 words will be removed.

    3) Label entity information: We refer to a large number of annotation specifications [28, 29] to label entity information. The CEHR corpus contains 3 types of entities: symptom (Sym), medicine (Med), and abnormal inspection result (Abn). Sym: Symptom refers to the subjective feelings described by the patient or the objective facts observed by the outside world, such as dizziness. Med: Medicine refers to the name of the medicine used in the process of treatment, excluding dosage, method of administration, etc. such as aspirin. Abn: Abnormal inspection result refers to abnormal changes and abnormal examination results that occur in patients through examination procedures or as observed by doctors, such as lung marking increase.

    After the above processing, we selected 8290 CEHRs as experimental data, and further splitted the CEHRs by 70, 10 and 20% as training, validation, and test sets, respectively. Table 2 shows the distribution of CEHRs, in descending order of data volume. The statistics of the entity information for our experiments are shown in Table 3.

    Table 2.  Number of training, validation and test sets for each disease in CEHR.
    Disease Training set Test set Validation set
    CI 700 200 100
    VBI 700 200 100
    CAHD 700 200 100
    bronchitis 700 200 100
    degenerative spondylitis 700 200 100
    T2DM 700 200 100
    other diseases 700 200 100
    cholecystitis 511 146 73
    intestinal obstruction 392 112 56

     | Show Table
    DownLoad: CSV
    Table 3.  Statistical table of entity information in CEHR.
    Disease Avg number Max number Min number
    CI 16.83 23 9
    VBI 13.71 20 8
    CAHD 15.16 27 7
    bronchitis 17.47 29 6
    degenerative spondylitis 12.18 14 5
    T2DM 16.38 32 8
    other diseases 16.08 33 6
    cholecystitis 18.94 30 9
    intestinal obstruction 16.16 27 8

     | Show Table
    DownLoad: CSV

    The goal of this paper is to get the EHR features and use them for disease prediction. Using evaluation metrics for classification tasks to assess the quality of disease prediction, such as Accuracy, Precision, Recall and F1-score, these are defined as follows:

    Accuracy=TP+TNTP+TN+FP+FN (4.1)
    Recall=TPTP+FN (4.2)
    Precision=TPTP+FP (4.3)
    F1score=2×Precision×RecallPrecision+Recall (4.4)

    where TP indicates the number of positive samples that were predicted as positive, FP indicates the number of negative samples that were predicted as positive and FN indicates the number of positive samples that were predicted to be negative. TN indicates the number of negative samples that were predicted as negative.

    In order to protect the patient privacy and data denoising, EHRs in this paper are preprocessed in various ways, such as privacy removing, data cleaning, entity labeling and disease standardizing. The version of the BERT model is BERT-base-Chinese, the main super-parameter is the size of hidden layer, which we set at 768, the Transformer blocks are 12, the number of attention heads is 12, and maximum input length is 512. In the convolutional module, the heights of the filters are 2, 3 and 4. During the training, we applied the learning rate of 5e-5 and the dropout rate of 0.5, and the batch size is 32.

    We conducted experiments to compare the performance of our model with other disease prediction models.

    SVM [5]: PKUSEG is a tool for word segmentation of Chinese EHRs. Then, the TF-IDF algorithm is used for extracting key information to obtain the representation of Chinese EHRs and then use SVM for disease prediction.

    CNN [15]: CNN is used for obtaining features from Chinese EHRs, and then the probability of the patient's disease can be computed by sending features to fully connected layers.

    BiLSTM: The model utilizes BiLSTM to extract features and feed them into fully connected activation layers for disease prediction.

    RCNN [30]: The model utilizes RCNN to obtain the textual features of EHRs, and then sends them into fully connected layers and activation layers for disease prediction.

    BERT [23]: The model uses the pre-trained model BERT to extract the features of Chinese EHRs for disease prediction tasks.

    We compared overall performance of our proposed model with baseline models on a test set of CEHR datasets. Table 4 shows the experimental results of baseline models and our proposed model.

    Table 4.  The comparison of each model for disease prediction results.
    Method Accuracy (%) Precision (%) Recall (%) F1-score (%)
    SVM 89.06 87.39 86.91 87.15
    CNN 89.55 88.44 87.55 87.99
    BiLSTM 89.39 88.53 86.97 87.74
    RCNN 89.76 89.04 87.51 88.27
    BERT 91.68 90.83 89.26 90.04
    Our-model 94.66 93.62 90.28 91.92

     | Show Table
    DownLoad: CSV

    As shown in Table 4, we can see that our method is more effective than other methods, and the F1-score reaches 91.92%. The methods in Table 4 can be divided into traditional machine learning and deep learning methods. SVM, as a traditional machine learning model, cannot deeply learn the complex feature representation of EHRs. The BERT model only obtains the text information of the EHRs, while ignoring the entity and numerical information, which leads our model to improve the F1-score of the mainstream BERT model by 1.88%. It means that entity information is very important for both patient representation and disease prediction. The experimental results show that the multi-type data fusion model can fully obtain the features of Chinese EHRs, and it is effective and feasible to conduct disease prediction based on this model.

    As shown in Table 5, 8 kinds of disease and other diseases are in descending order of data volume (the number of each disease is shown in Table 2). We list the F1-score corresponding to each disease. Our model has the highest F1-score in all 8 kinds of diseases and other diseases, indicating that we can effectively represent patients in these 8 kinds of diseases and other diseases. In terms of the diseases with fewer quantities of data, our model shows a significant performance improvement compared to other baseline models, such as cholecystitis, and intestinal obstruction, which improved by 2.61% to 2.5%. For VBI and degenerative spondylitis, our model has less improvement, 1.25 and 1.31%, respectively. The main reason is that due to the small number of entities in these two diseases, the model cannot learn the features of entity information well.

    Table 5.  Experimental results of different models on each disease.
    Disease SVM CNN BiLSTM RCNN BERT Our model
    CI 82.26 82.91 82.94 83.38 86.41 88.78
    VBI 82.45 83.19 83.83 86.27 87.18 88.43
    CAHD 89.72 90.74 90.43 90.88 92.03 93.83
    bronchitis 89.79 89.87 90.17 90.59 93.48 95.15
    degenerative spondylitis 89.91 90.14 89.81 90.41 90.22 91.53
    T2DM 90.37 90.91 89.85 89.49 91.48 93.43
    other diseases 84.27 86.23 85.17 85.94 88.54 89.96
    cholecystitis 88.69 89.72 88.75 88.35 90.91 93.52
    intestinal obstruction 86.89 88.23 88.72 89.14 90.18 92.68

     | Show Table
    DownLoad: CSV

    To verify the importance and role of different types of information on CEHR representation and to better understand the behavior of the proposed fusion model, we employ an ablation study and conduct extensive experiments on different models. T, E and N represent textual information, entity information and numerical information, respectively. As shown in Table 6, using T + E + N, the model achieved 91.92% F1-score in the test set, which is 1.09, 1.56 and 0.75% higher than of the models without textual, entity and numerical information, indicating that different types of information have an impact on disease prediction. Among them, entity information has the greatest impact on the model, which shows that entity information plays a key role in our model. By fusing multiple types of data, the performance of the model is improved, and at the same time, the model is more explanatory.

    Table 6.  Results with different type information.
    Method Precision (%) Recall (%) F1-score (%)
    T + E + N 93.62 90.28 91.92
    T + E 92.18 90.18 91.17
    T + N 91.69 89.06 90.36
    E + N 91.19 90.47 90.83

     | Show Table
    DownLoad: CSV

    In order to choose a better entity acquisition method, we compared the CRF and BiLSTM-CRF models, and the results are shown in Figure 4.

    Figure 4.  Comparison of CRF and BiLSTM-CRF models.

    We performed a comparison of the CRF and BiLSTM-CRF models for the identification of entity information in CEHRs. The Precisions for the two models are 88.57 and 89.24%. The Recalls for the two models are 87.54 and 88.76%. The F1-scores for the two models are 88.05 and 89.01%. We find that the BiLSTM-CRF model outperforms the CRF model. So, the BiLSTM-CRF model is selected as the entity extraction model in CEHRs.

    Multi-head attention was adopted to fuse textual information and numerical information. As shown in Figure 5, when the number of heads of the multi-head attention is 8, the model achieves the best performance, with an F1-score of 91.92%. As the number of heads increases, the performance of the model gets better, but the number of heads should not be set too large, as otherwise F1-score will decrease. When the number of heads reached 12, the F1-score decreased by 0.31%, because excessive attention would introduce noise and reduce the performance of the model.

    Figure 5.  F1-score under different head numbers.

    The purpose of this experiment is to study whether the EHRs representation adopted in the BERT model is better than the traditional Word2vec and Doc2vec in effect. As shown in Table 7, the effect of using BERT as text and entity embedding is better than Word2vec and Doc2vec embeddings, and the F1-score of the BERT model is 3.17% better than that of the Word2vec+Doc2vec combined model. The reason is that the training method of the BERT model based on character vectors can alleviate the problem of polysemy to a certain extent.

    Table 7.  Experimental effect of BERT model.
    Model Precision (%) Recall (%) F1-score (%)
    Word2vec+Doc2vec 89.15 88.36 88.75
    Our-model 93.62 90.28 91.92

     | Show Table
    DownLoad: CSV

    This paper proposes a disease prediction method based on a multi-type data fusion mechanism for EHRs. The model uses multi-head self-attention to fuse numerical features into textual information and enhance text representation. Using the TextCNN model to formulate entity representation, the representations of text and entities in it are mixed together to obtain the final representation of the EHR. This method solves the problems of unreasonable representation and difficulty in feature extraction when various data of EHRs exist. The experimental results show that the multi-type data fusion model can effectively learn the feature representation of EHRs and achieve disease prediction. In future work, we will try to incorporate more information, such as time series data, external knowledge bases, etc., to further improve the quality and efficiency of disease prediction.

    We would like to thank the anonymous reviewers for their valuable comments. The Publication of the article is supported by the National Natural Science Foundation of China (No. 62163033), the Natural Science Foundation of Gansu Province (No. 21JR7RA781, No. 21JR7RA116), Lanzhou Talent Innovation and Entrepreneurship Project (No. 2021-RC-49) and Northwest Normal University Major Research Project Incubation Program (No. NWNU-LKZD2021-06).

    The authors declare there is no conflict of interest.



    [1] F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, L. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68 (2018), 394-424. https://doi.org/10.3322/caac.21492 doi: 10.3322/caac.21492
    [2] T. Greten, C. Lai, G. Li, K. Staveley-O' Carroll, targeted and immune-based therapies for hepatocellular carcinoma, Gastroenterology, 156 (2019), 510-524. https://doi.org/10.1053/j.gastro.2018.09.051 doi: 10.1053/j.gastro.2018.09.051
    [3] J. Llovet, R. Montal, D. Sia, R. Finn, Molecular therapies and precision medicine for hepatocellular carcinoma, Nat. Rev. Clin. Oncol., 15 (2018), 599-616. https://doi.org/10.1038/s41571-018-0073-4 doi: 10.1038/s41571-018-0073-4
    [4] Y. Jiang, A. Sun, Y. Zhao, W. Ying, H. Sun, X. Yang, et al., Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma, Nature, 567 (2019), 257-261. https://doi.org/10.1038/s41586-019-0987-8 doi: 10.1038/s41586-019-0987-8
    [5] C. Qu, Y. Wang, P. Wang, K. Chen, M. Wang, H. Zeng, et al., Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy, Proc. Natl. Acad. Sci. U. S. A., 116 (2019), 6308-6312. https://doi.org/10.1073/pnas.1819799116 doi: 10.1073/pnas.1819799116
    [6] S. Torrecilla, D. Sia, A. Harrington, Z. Zhang, L. Cabellos, H. Cornella, et al., Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma, J. Hepatol., 67 (2017), 1222-1231. https://doi.org/10.1016/j.jhep.2017.08.013 doi: 10.1016/j.jhep.2017.08.013
    [7] C. Cainap, S. Qin, W. Huang, I. Chung, H. Pan, Y. Cheng, et al., Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 33 (2015), 172-179. https://doi.org/10.1200/jco.2013.54.3298 doi: 10.1200/jco.2013.54.3298
    [8] Y. Sun, Y. Xu, X. Yang, W. Guo, X. Zhang, S. Qiu, et al., Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection, Hepatology, 57 (2013), 1458-1468. https://doi.org/10.1002/hep.26151 doi: 10.1002/hep.26151
    [9] J. Nault, A. Villanueva, Intratumor molecular and phenotypic diversity in hepatocellular carcinoma, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 21 (2015), 1786-1788. https://doi.org/10.1158/1078-0432.ccr-14-2602 doi: 10.1158/1078-0432.ccr-14-2602
    [10] L. Dong, L. Peng, L. Ma, D. Liu, S. Zhang, S. Luo, et al., Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma, J. Hepatol., 72 (2020), 896-908. https://doi.org/10.1016/j.jhep.2019.12.014 doi: 10.1016/j.jhep.2019.12.014
    [11] S. Tella, A. Mahipal, A. Kommalapati, Z. Jin, Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to Date, Oncol. Targets Ther., 12 (2019), 10335-10342. https://doi.org/10.2147/ott.s214870 doi: 10.2147/ott.s214870
    [12] P. Galle, R. Finn, S. Qin, M. Ikeda, A. Zhu, T. Kim, et al., Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial, Lancet Oncol., 22 (2021), 991-1001. https://doi.org/10.1016/s1470-2045(21)00151-0 doi: 10.1016/s1470-2045(21)00151-0
    [13] H. Tan, N. Wang, C. Zhang, Y. Chan, M. Yuen, Y. Feng, Lysyl oxidase-like 4 fosters an immunosuppressive microenvironment during hepatocarcinogenesis, Hepatology, 73 (2021), 2326-2341. https://doi.org/10.1002/hep.31600 doi: 10.1002/hep.31600
    [14] M. Wu, X. Xia, J. Hu, N. Fowlkes, S. Li, WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression, Nat. Commun., 12 (2021), 3500. https://doi.org/10.1038/s41467-021-23864-9 doi: 10.1038/s41467-021-23864-9
    [15] X. Liu, M. Li, X. Wang, Z. Dang, Y. Jiang, X. Wang, et al., PD-1 TIGIT CD8 T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma, Cancer Immunol. Immunother., 68 (2019), 2041-2054. https://doi.org/10.1007/s00262-019-02426-5 doi: 10.1007/s00262-019-02426-5
    [16] S. Itoh, T. Yoshizumi, K. Yugawa, D. Imai, S. Yoshiya, K. Takeishi, et al., Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation, Hepatology, 72 (2020), 1987-1999. https://doi.org/10.1002/hep.31206 doi: 10.1002/hep.31206
    [17] F. Liu, Y. Liu, Z. Chen, Tim-3 expression and its role in hepatocellular carcinoma, J. Hematol. Oncol., 11 (2018), 126. https://doi.org/10.1186/s13045-018-0667-4 doi: 10.1186/s13045-018-0667-4
    [18] M. Guo, F. Yuan, F. Qi, J. Sun, Q. Rao, Z. Zhao, et al., Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8T cells in hepatocellular carcinoma using multiplex quantitative analysis, J. Transl. Med., 18 (2020), 306. https://doi.org/10.1186/s12967-020-02469-8 doi: 10.1186/s12967-020-02469-8
    [19] K. Sideras, K. Biermann, J. Verheij, B. Takkenberg, S. Mancham, B. Hansen, et al., PD-L1, Galectin-9 and CD8 tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma, Oncoimmunology, 6 (2017), e1273309. https://doi.org/10.1080/2162402x.2016.1273309 doi: 10.1080/2162402x.2016.1273309
    [20] X. Shen, B. Zhao, Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis, BMJ, 362 (2018), k3529. https://doi.org/10.1136/bmj.k3529 doi: 10.1136/bmj.k3529
    [21] F. Hu, C. Liu, L. Liu, Q. Zhang, A. Guo, Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response, Briefings Bioinf., 22 (2021), 176. https://doi.org/10.1093/bib/bbaa176 doi: 10.1093/bib/bbaa176
    [22] D. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12 (2012), 252-264. https://doi.org/10.1038/nrc3239 doi: 10.1038/nrc3239
    [23] K. Campbell, A. Purdy, Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations, Immunology, 132 (2011), 315-325. https://doi.org/10.1111/j.1365-2567.2010.03398.x doi: 10.1111/j.1365-2567.2010.03398.x
    [24] H. Afrache, P. Gouret, S. Ainouche, P. Pontarotti, D. Olive, The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response, Immunogenetics, 64 (2012), 781-794. https://doi.org/10.1007/s00251-012-0619-z doi: 10.1007/s00251-012-0619-z
    [25] P. Charoentong, F. Finotello, M. Angelova, C. Mayer, M. Efremova, D. Rieder, et al., Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade, Cell Rep., 18 (2017), 248-262. https://doi.org/10.1016/j.celrep.2016.12.019 doi: 10.1016/j.celrep.2016.12.019
    [26] Y. Dai, W. Qiang, K. Lin, Y. Gui, X. Lan, D. Wang, An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma, Cancer Immunol. Immunother., 70 (2021), 967-979. https://doi.org/10.1007/s00262-020-02743-0 doi: 10.1007/s00262-020-02743-0
    [27] X. Hua, S. Ge, J. Zhang, H. Xiao, S. Tai, C. Yang, et al., A costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma, Cell Death Discovery, 7 (2021), 252. https://doi.org/10.1038/s41420-021-00646-2 doi: 10.1038/s41420-021-00646-2
    [28] A. El-Khoueiry, B. Sangro, T. Yau, T. Crocenzi, M. Kudo, C. Hsu, et al., Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389 (2017), 2492-2502. https://doi.org/10.1016/s0140-6736(17)31046-2 doi: 10.1016/s0140-6736(17)31046-2
    [29] A. Zhu, R. Finn, J. Edeline, S. Cattan, S. Ogasawara, D. Palmer, et al., Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet. Oncol., 19 (2018), 940-952. https://doi.org/10.1016/s1470-2045(18)30351-6 doi: 10.1016/s1470-2045(18)30351-6
    [30] Z. Liu, X. Liu, J. Liang, Y. Liu, X. Hou, M. Zhang, et al., Immunotherapy for hepatocellular carcinoma: current status and future prospects, Front. Immunol., 12 (2021), 765101. https://doi.org/10.3389/fimmu.2021.765101 doi: 10.3389/fimmu.2021.765101
    [31] E. Zhao, S. Chen, Y. Dang, Development and external validation of a novel immune checkpoint-related gene signature for prediction of overall survival in hepatocellular carcinoma, Front. Mol. Biosci., 7 (2020), 620765. https://doi.org/10.3389/fmolb.2020.620765 doi: 10.3389/fmolb.2020.620765
    [32] S. Kim, H. Lee, M. Jeon, T. Yi, S. Song, Galectin-9 is involved in immunosuppression mediated by human bone marrow-derived clonal mesenchymal stem cells, Immune Network, 15 (2015), 241-251. https://doi.org/10.4110/in.2015.15.5.241 doi: 10.4110/in.2015.15.5.241
    [33] T. Kageshita, Y. Kashio, A. Yamauchi, M. Seki, M. Abedin, N. Nishi, et al., Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance, Int. J. Cancer, 99 (2002), 809-816. https://doi.org/10.1002/ijc.10436 doi: 10.1002/ijc.10436
    [34] A. Irie, A. Yamauchi, K. Kontani, M. Kihara, D. Liu, Y. Shirato, et al., Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 11 (2005), 2962-2968. https://doi.org/10.1158/1078-0432.ccr-04-0861 doi: 10.1158/1078-0432.ccr-04-0861
    [35] S. Chen, J. Pu, J. Bai, Y. Yin, K. Wu, J. Wang, et al., EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis, J. Exper. Clin. Cancer Res., 37 (2018), 3. https://doi.org/10.1186/s13046-017-0670-6 doi: 10.1186/s13046-017-0670-6
    [36] S. Schoenberger, R. Toes, E. van der Voort, R. Offringa, C. Melief, T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions, Nature, 393 (1998), 480-483. https://doi.org/10.1038/31002 doi: 10.1038/31002
    [37] M. Gonzalez-Carmona, V. Lukacs-Kornek, A. Timmerman, S. Shabani, M. Kornek, A. Vogt, et al., CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo, Hepatology, 48 (2008), 157-168. https://doi.org/10.1002/hep.22296 doi: 10.1002/hep.22296
    [38] Y. Pan, Y. Tan, M. Wang, J. Zhang, B. Zhang, C. Yang, et al., Signal regulatory protein α is associated with tumor-polarized macrophages phenotype switch and plays a pivotal role in tumor progression, Hepatology, 58 (2013), 680-691. https://doi.org/10.1002/hep.26391 doi: 10.1002/hep.26391
    [39] M. Yuan, X. Zhang, J. Zhang, K. Wang, Y. Zhang, W. Shang, et al., DC-SIGN-LEF1/TCF1-miR-185 feedback loop promotes colorectal cancer invasion and metastasis, Cell Death Differ., 27 (2020), 379-395. https://doi.org/10.1038/s41418-019-0361-2 doi: 10.1038/s41418-019-0361-2
    [40] W. Ma, J. Liang, J. Mo, S. Zhang, N. Hu, D. Tian, et al., Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma, BMC Cancer, 21 (2021), 1096. https://doi.org/10.1186/s12885-021-08790-9 doi: 10.1186/s12885-021-08790-9
    [41] Y. Li, Y. Chen, L. Miao, Y. Wang, M. Yu, X. Yan, et al., Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells, Cancer Lett., 497 (2021), 212-220. https://doi.org/10.1016/j.canlet.2020.10.032 doi: 10.1016/j.canlet.2020.10.032
    [42] W. Fridman, F. Pagès, C. Sautès-Fridman, J. Galon, The immune contexture in human tumours: impact on clinical outcome, Nat. Rev. Cancer, 12 (2012), 298-306. https://doi.org/10.1038/nrc3245 doi: 10.1038/nrc3245
    [43] K. Kesh, V. Garrido, A. Dosch, B. Durden, V. Gupta, N. Sharma, et al., Stroma secreted IL6 selects for "stem-like" population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways, Cell Death Dis., 11 (2020), 967. https://doi.org/10.1038/s41419-020-03168-4 doi: 10.1038/s41419-020-03168-4
    [44] F. Kohlhapp, J. Broucek, T. Hughes, E. Huelsmann, J. Lusciks, J. Zayas, et al., NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade, J. Immunother. Cancer, 3 (2015), 18. https://doi.org/10.1186/s40425-015-0063-3 doi: 10.1186/s40425-015-0063-3
  • mbe-19-05-220-supplementary.pdf
  • Reader Comments
  • © 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(3754) PDF downloads(146) Cited by(1)

Figures and Tables

Figures(8)  /  Tables(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog